Dashboard
Poor Management Efficiency with a low ROCE of 3.61%
- The company has been able to generate a Return on Capital Employed (avg) of 3.61% signifying low profitability per unit of total capital (equity and debt)
High Debt Company with a Debt to Equity ratio (avg) at times
Poor long term growth as Net Sales has grown by an annual rate of 6.18% and Operating profit at 9.96% over the last 5 years
Negative results in Jun 25
Risky -
Stock DNA
Specialty Chemicals
CNY 3,807 Million (Small Cap)
NA (Loss Making)
NA
0.51%
0.47
-2.47%
1.71
Total Returns (Price + Dividend) 
Xilong Scientific Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Xilong Scientific Hits Day Low of CNY 8.90 Amid Price Pressure
Xilong Scientific Co., Ltd. has faced a notable stock decline amid a challenging market, reaching an intraday low. Despite a year-to-date increase, recent performance metrics indicate a downturn. The company struggles with low management efficiency and high leverage, compounded by declining net profit and sales in recent quarters.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is -4.60% vs 36.74% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is -1,030.00% vs 550.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 10.19% vs 14.74% in Dec 2023
YoY Growth in year ended Dec 2024 is 82.08% vs -60.55% in Dec 2023






